Multiomics

Structure of the eye
#Mogrify #Preclinical development #Retinal diseases #Transcriptomics

MOGRIFY-derived transcription factors preserve functional vision

Mogrify will present preclinical proof-of-concept data at FLORetina-ICOOR 2026 in support its first-in-class therapy designed to protect and regenerate the retina in patients with retinal disorders.  The company’s lead programme uses transcription factor-mediated direct reprogramming to convert müller glial cells into functional photoreceptors within the retina.  … Read More

#News

#Cascade #Immune response #Nomic Bio #Parse Biosciences #Proteomics #QIAGEN #RNA sequencing #Single-cell RNA sequencing

Large-scale immune response dataset partnership

Proteomics company Nomic Bio and Parse Biosciences, a provider of single-cell sequencing and a QIAGEN company, have partnered to generate Cascade, a large-scale multimodal dataset designed to establish a foundational reference for healthy human immune response. Built using controlled perturbations across healthy donors, Cascade combines single-cell transcriptomic measurements with quantitative… Read More

#News

#Flagship Pioneering #Foundational model #Start-ups #Transcriptomics

New company Etcelera unites three drug discovery platforms

Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics.  The new company aims to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine… Read More

#Business & Investment #News #Start-up Zone

#AI / data analytics / healthtech / informatics #Bioinformatics #Drug discovery #Genomics #QUIAGEN

QIAGEN expands AI-powered bioinformatics for research and drug discovery   

QIAGEN’s new artificial intelligence (AI) capabilities will reportedly help researchers analyse complex biological and genomic data faster while keeping the scientific evidence behind the results visible.  The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery… Read More

#News

#Advertorial #Epigenomics #Genomics #Mutliomics #Neurological disease #Sampled

From genomics to multiomics: A broader view of neurological disease

In this paid-for advertorial for the Fall 2026 issue of DDW, Sampled shares insight on neurological disease with a genomics and multiomics lens.  Genomic testing can identify drivers of neurological disease, but many variants remain difficult to interpret. Multiomics helps to close this gap by connecting genetic findings with… Read More

#Exclusive Content

#Drug discovery #Genetics #Genomics #Target discovery

From disease genetics to more effective medicines 

Dr James Heward, VP Functional Genomics at Nucleome Therapeutics, discusses what could be the missing link in the chain of causality from patient to target to drug.   The fundamental question that stalks every drug discovery project is “will this drug fail?” Most do. There is no single reason for more than 90% of clinical… Read More

#Exclusive Content

AI and genomics
#Artificial intelligence (AI) #Funding #Genomics #Innovate UK #OutSee

OutSee receives Innovate UK grant for agentic AI pilot study

Genomics drug discovery company OutSee has been awarded funding through Innovate UK’s Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures.   The grant will enable OutSee to conduct a pilot study for a prototype target validation sub-system, designed for initial triage of potential drug targets… Read More

#News

Cancer cells
#Drug discovery #Epigenetics #Genomics #Oncology

How Oryzon Genomics is using epigenetics to tackle cancer  

DDW Editor Reece Armstrong speaks to Dr Carlos Buesa, Founder and CEO of Oryzon Genomics, about epigenetic approaches to treating cancer and the company’s current journey within drug discovery and development.   RA: Can an epigenetic approach help tackle aggressive cancers and those with poor prognoses?  CB: Yes. Many aggressive cancers are… Read More

#Exclusive Content

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Available on-demand: How DRUG-seq enables data-rich compound screening

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Don’t forget to watch: Building the data layer for AI drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Cambridge Omics Centre #Drug discovery #Metabolomics #Multiomics #Novogene Europe

Novogene Europe launches untargeted metabolomics service

Multiomics research services partner Novogene Europe has launched its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers across the UK and Europe to connect molecular data with biological function by adding metabolite-level insight to genomics, transcriptomics, microbiome and broader life science studies. Untargeted Metabolomics… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Watch now: Building data with phenotypic and transcriptomic workflows

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Webinar: Learn how to build rich datasets for drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News

#Artificial intelligence (AI) #High throughput screening #Transcriptomics #Webinar

Webinar: Building the data layer for AI drug discovery

AI-driven drug discovery depends on large-scale, information-rich biological datasets that capture how compounds perturb cellular systems across diverse conditions. Building these datasets requires scalable approaches that can combine phenotypic and molecular readouts in high-throughput screening workflows. In this webinar, hosted by DDW, Daniel Alpern, Chief Scientific Officer at… Read More

#News